Dong Shin, MD
Internal Medicine · Los Angeles, CANPI 1740387646
Payments from drug & device makers
Across 286 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$873
- Bayer$494
- Takeda Pharmaceuticals U.S.A., Inc.$473
- GSK$371
- Johnson & Johnson$221
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,131100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,271 |
| AbbVie(2 entities) | 44 | $873 |
| Bayer | 21 | $494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $473 |
| GSK | 19 | $371 |
| Johnson & Johnson | 8 | $221 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $220 |
| Boehringer Ingelheim | 9 | $219 |
| Lilly USA, LLC | 10 | $219 |
| Sumitomo Pharma America, Inc. | 10 | $200 |
| Novo Nordisk | 9 | $181 |
| Nestle Healthcare Nutrition Inc. | 8 | $178 |
| Amarin Pharma, Inc. | 6 | $135 |
| Merck | 7 | $135 |
| Amgen | 4 | $105 |
| Redhill Biopharma Inc. | 5 | $103 |
| E.r. Squibb & Sons, L.L.C. | 4 | $94 |
| Corium, LLC | 3 | $90 |
| Eisai Inc. | 4 | $89 |
| Pfizer | 3 | $75 |
| Ironwood Pharmaceuticals, Inc | 3 | $71 |
| Scilex Pharmaceuticals Inc. | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| Vivus LLC | 2 | $33 |
| Gilead | 1 | $30 |
| Digestive Care, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$109
How this compares
$6,160 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 409 | $450,606 |
| FarxigaDapagliflozin Propanediol | 708 | $424,908 |
| VascepaIcosapent Ethyl | 644 | $215,468 |
| KerendiaFinerenone | 288 | $187,038 |
| LinzessLinaclotide | 315 | $169,102 |
| JanuviaSitagliptin Phosphate | 234 | $136,958 |
| ZenpepLipase/Protease/Amylase | 117 | $133,891 |
| TrulicityDulaglutide | 143 | $133,570 |
| RestasisCyclosporine | 190 | $123,191 |
| JardianceEmpagliflozin | 212 | $114,018 |
| EliquisApixaban | 219 | $106,903 |
| TradjentaLinagliptin | 230 | $101,964 |
| OzempicSemaglutide | 81 | $80,639 |
| NamzaricMemantine Hcl/Donepezil Hcl | 101 | $58,291 |
| DapagliflozinDapagliflozin Propanediol | 144 | $56,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis, Namzaric | $873 | $801,1891,015 claims |
| AstraZenecaFarxiga, Brilinta | $1,271 | $443,470765 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Jentadueto | $219 | $275,594564 claims |
| BayerKerendia | $494 | $187,038288 claims |
| MerckJanuvia, Janumet, Janumet Xr | $135 | $163,701293 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $219 | $152,658162 claims |
| PfizerEliquis | $75 | $106,903219 claims |
| Novo NordiskOzempic, Rybelsus | $181 | $91,03092 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $473 | $56,146112 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $200 | $55,159116 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $371 | $40,22772 claims |
| AmgenProlia | $105 | $38,99323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.